Abbott Laboratories (NYSE:ABT) Stock Purchase Revealed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on September 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Abbott Laboratories Trading Up 0.4%

ABT opened at $103.04 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a market capitalization of $178.29 billion, a price-to-earnings ratio of 33.35, a PEG ratio of 1.90 and a beta of 0.59. The business has a fifty day moving average price of $106.03 and a 200 day moving average price of $98.26. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $132.02.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. Sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analyst Weigh In

ABT has been the subject of several recent research reports. TD Cowen reaffirmed a “buy” rating and set a $135.00 price target on shares of Abbott Laboratories in a report on Tuesday, September 8th. Barclays assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective on the stock. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.88.

Hedge Funds Weigh In On Abbott Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of ABT. BlackRock Inc. increased its position in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares during the period. State Street Corp boosted its holdings in shares of Abbott Laboratories by 1.7% during the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after buying an additional 1,350,766 shares in the last quarter. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Abbott Laboratories by 0.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock worth $2,241,076,000 after acquiring an additional 118,014 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of Abbott Laboratories in the 2nd quarter worth about $1,603,607,000. 75.18% of the stock is owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.